Subscribe
mylan-epipen
Amy Kerkemeyer / shutterstock.com
11 October 2016Americas

Mylan to pay US government $465m over EpiPen

Mylan has agreed to pay the US Department of Justice and other government agencies $465 million to settle questions about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan finalises $465m settlement with US government
18 August 2017   Mylan has finalised a $465 million payment to the US government to settle a lawsuit about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.
Big Pharma
EPO gears up to hear EpiPen patent opposition
27 February 2018   The European Patent Office will hear an opposition against a patent covering Mylan’s EpiPen at the end of March.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Mylan finalises $465m settlement with US government
18 August 2017   Mylan has finalised a $465 million payment to the US government to settle a lawsuit about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.
Big Pharma
EPO gears up to hear EpiPen patent opposition
27 February 2018   The European Patent Office will hear an opposition against a patent covering Mylan’s EpiPen at the end of March.

More on this story

Americas
Mylan finalises $465m settlement with US government
18 August 2017   Mylan has finalised a $465 million payment to the US government to settle a lawsuit about the classification of EpiPen Auto-Injector (epinephrine) under the Medicaid Drug Rebate Program.
Big Pharma
EPO gears up to hear EpiPen patent opposition
27 February 2018   The European Patent Office will hear an opposition against a patent covering Mylan’s EpiPen at the end of March.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility